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objeCtive Glioma heterogeneity and the limitations of conventional structural MRI for identifying aggressive tumor 
components can limit the reliability of stereotactic biopsy and, hence, tumor characterization, which is a hurdle for devel-
oping and selecting effective treatment strategies. In vivo MR spectroscopy (MRS) and PET enable noninvasive imaging 
of cellular metabolism relevant to proliferation and can detect regions of more highly active tumor. Here, the authors 
integrated presurgical PET and MRS with intraoperative neuronavigation to guide surgical biopsy and tumor sampling of 
brain gliomas with the aim of improving intraoperative tumor-tissue characterization and imaging biomarker validation.
MethoDs A novel intraoperative neuronavigation tool was developed as part of a study that aimed to sample high-
choline tumor components identified by multivoxel MRS and 18F-methylcholine PET-CT. Spatially coregistered PET and 
MRS data were integrated into structural data sets and loaded onto an intraoperative neuronavigation system. High and 
low choline uptake/metabolite regions were represented as color-coded hollow spheres for targeted stereotactic biopsy 
and tumor sampling.
resUlts The neurosurgeons found the 3D spherical targets readily identifiable on the interactive neuronavigation sys-
tem. In one case, areas of high mitotic activity were identified on the basis of high 18F-methylcholine uptake and elevated 
choline ratios found with MRS in an otherwise low-grade tumor, which revealed the possible use of this technique for 
tumor characterization.
ConClUsions These PET and MRI data can be combined and represented usefully for the surgeon in neuronaviga-
tion systems. This method enables neurosurgeons to sample tumor regions based on physiological and molecular imag-
ing markers. The technique was applied for characterizing choline metabolism using MRS and 18F PET; however, this 
approach provides proof of principle for using different radionuclide tracers and other MRI methods, such as MR perfu-
sion and diffusion.
http://thejns.org/doi/abs/10.3171/2016.7.JNS16106
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HigH-resolution MR images, acquired presurgically, are commonly used in intraoperative neuronaviga-tion systems to guide stereotactic biopsy and tumor 
resection.12 Regions of pathological contrast enhancement 
on Gd-enhanced T1-weighted images and T2-dependent 
signal abnormality on T2-weighted and FLAIR images are 
typically used to define surgical targets. Spatial heterogene-
ity in gliomas and poor biological specificity of these con-
ventional MRI sequences limit tumor characterization and, 
hence, clinical decision making for postsurgical phases of 
treatment. Indeed, the histopathological diagnosis from ste-
reotactic biopsy using standard imaging has been shown to 
disagree with that from the resected tumor in almost 50% 
of patients when reviewed by a single histopathologist.6
Imaging modalities that can detect the most aggressive 
tumor elements and delineate tumor margins are being 
developed. Multimodal MRI, which incorporates quan-
titative and physiological methods such as in vivo MR 
spectroscopy (MRS), and molecular imaging with PET 
tracers yield additional information on tumor metabolism 
and cellular turnover and have been shown to augment the 
information available from structural imaging. Validation 
©AANS, 2016 j neurosurg November 11, 2016 1
M. grech-sollars et al.
j neurosurg November 11, 20162
of these imaging biomarkers against tumor biology is es-
sential, and integrating such images in neurosurgical plan-
ning is required.
The use of a number of different imaging techniques 
was explored previously for guiding neurooncological 
surgery.10,18 MRS data also have been incorporated into 
neuronavigational systems;10,17,20 however, those studies did 
not involve direct spatial location of MRS information di-
rectly onto high-resolution T1-weighted images. MRS also 
requires offline processing, analysis, and interpretation to 
exclude artifacts and errors7 before it can be used to iden-
tify surgical targets. PET has also been applied to guiding 
biopsy and surgical tumor resection.8,11,15
Here, we describe the successful integration of MRS 
and PET into intraoperative neuronavigational systems for 
advanced biopsy and tumor-sample targeting in a clinical 
environment.
Methods
A surgical planning tool was required as part of a pro-
spective single-center cohort study that aimed to compare 
18F-methylcholine (FMC) uptake on PET and elevated 
choline-containing compound (Cho) levels on MRS 
against tissue markers of Cho metabolism. (Throughout 
the article, Cho refers to choline-containing compounds as 
defined in MRS, and FMC refers to 18F-methylcholine in 
PET; choline is a generic term that refers to either MRS 
or PET.) The technique presented here was developed on 
the cohort of 14 patients recruited for that study. These pa-
tients had a diagnosis of primary brain tumor on imaging 
and were undergoing a biopsy or resection of their tumor 
within a few months of imaging. Surgery took place be-
tween 1 day and 8 weeks after the MRS and PET images 
were acquired. Ethical approval was given by the National 
Research Ethics Service Committee London–Fulham, and 
informed consent was obtained from each participant. All 
data were anonymized in accordance with the UK Data 
Protection Act.
image acquisition
MR images were acquired on a 3-T Verio VB19 MRI 
system (Siemens) using a 32-channel head coil. The MRI 
protocol included pre-Gd and post-Gd high-resolution 3D 
volumetric T1-weighted imaging (voxel size 1 × 1 × 1 mm) 
and multivoxel MRS using 2D chemical-shift imaging 
(CSI) point-resolved spectroscopy (PRESS) (TE 30 msec, 
TR 1700 msec, voxel size 10 × 10 × 15 mm); the total 
acquisition time for one CSI slice was 7 minutes. PET-CT 
was performed on a Siemens Biograph 6 scanner with CT 
at 120 kV, 5 mA, followed by a bolus injection of 285 MBq 
of FMC (PETNET Solutions) using a dedicated 45-minute 
brain dynamic list-mode acquisition.
image analysis and integration and surgical Planning
MRS data were analyzed using proprietary Siemens 
software and TARQUIN, which uses time domain–based 
algorithms for spectroscopic metabolite analysis.21 Ratios 
of Cho-containing compounds to creatine and phospho-
creatine (Cr) were calculated for each MRS voxel.
Time-activity curves from dynamically acquired FMC 
PET allowed time-averaged images to be calculated from 
averaged signal (last 10 minutes of dynamic acquisition 
from tracer injection) during a pseudo–steady-state phase 
(Hermes Diagnostics). Regions of tumoral uptake were 
identified visually from appropriately windowed images.
An imaging scientist with experience in physiological 
imaging of gliomas processed and analyzed the MRS and 
PET data after discussion with neuroradiologists experi-
enced in MRS and PET-CT imaging of gliomas. Voxels 
that indicated high and low Cho/Cr ratios on MRS and 
high uptake on PET were identified.
In the initial cases, the locations at which MRS and PET 
were to be sampled were discussed with the surgeons, and 
a hard copy of images showing the area to sample was pro-
vided. However, this process was found to be inaccurate 
and unreliable; hence, a surgical planning tool that could 
define regions to sample intraoperatively was required.
Spatial information was extracted from the DICOM 
MRS data set so that the targets could be overlaid on one 
of the images acquired in the same imaging session. The 
targets were overlaid on high-resolution postcontrast T1-
weighted structural images, which were acquired immedi-
ately before the MRS sequence to minimize the effects of 
registration error caused by any patient motion.
The first attempt at presenting these regions to the sur-
geons involved using a cross-type marker on the preopera-
tive axial images on one image slice. However, when they 
were viewed at an oblique angle, these markers were not 
clearly visible, and an improved method for representing 
the biopsy targets was required.
To generate readily visible surgical targets, image 
masks of hollow spheres were constructed around the indi-
vidual MRS voxels already identified using bespoke soft-
ware written in MATLAB (Fig. 1).
Similarly, hollow-sphere image masks were created 
for areas that showed high and low choline uptake on 
PET imaging by first registering the PET images to the 
MR images using Vinci software (http://www.nf.mpg.de/ 
vinci3/) and then identifying the locations of high FMC 
PET uptake. All of the regions selected for biopsy were 
then overlaid onto the presurgical high-resolution T1-
weighted image using a color-coded system to indicate 
which region identified with MRS or PET corresponded 
to each sphere. Thus, multiple target tumor-sampling areas 
were presented to the surgeons using color coding to iden-
tify if a sample was taken from an area identified through 
the PET data, the MRS data, or both. Masks were over-
laid using a custom-written MATLAB script, and images 
were saved in DICOM format. The resultant image (Fig. 
1 upper right) was then loaded to the neuronavigational 
system.
intraoperative guidance
The target images were loaded onto neuronavigational 
systems such that the color-coded spheres were easily vis-
ible in all planes and at oblique angles (Fig. 2). One of 2 
neuronavigational systems was used for 13 patients who 
underwent surgery in this study: a 3D ultrasound neuro-
navigation system (SonoWand Invite)5 in 9 patients (Fig. 2) 
or a Medtronic StealthStation in 4 patients (Fig. 3). For the 
StealthStation and an older SonoWand system, grayscale 
spheres were used to indicate the different areas in these 
Mrs- and Pet-guided biopsy tool for neuronavigational systems
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cases because these systems did not accept color DICOM 
images.
In addition to generating the image masks consisting of 
hollow spheres for each voxel, the software also generated 
a slab of all the voxel locations that could be overlaid on 
top of the structural MR and PET images to retrospec-
tively identify and confirm which voxel of MRS data cor-
responded to each of the samples taken during surgery.
After the registration of this integrated data set with 
the patient’s cranial position at the time of surgery, the 
surgical incision and craniotomy were planned to enable 
optimal access to the tumor-sampling areas identified. In 
each case, 1–5 stereotactic biopsies targeted to regions 
with high and low Cho/Cr ratios and FMC uptake were 
performed before any resection to minimize the effects of 
brain shift on the accuracy of the navigation system dur-
ing surgery. A neuronavigation-compatible passive biopsy 
needle was used to obtain frameless stereotactic tissue 
samples.
When a tumor sample was taken from the center of a 
sphere, the location was recorded on the navigation system 
together with the sample number to correlate accurately 
with histology. In cases in which the sample was not taken 
from the center of the sphere, the recorded positional data 
enabled the exact location of the sample to be determined. 
The corresponding MRS voxel and PET results were iden-
tified by overlaying the PET images and MRS voxel loca-
tions, as shown in Fig. 1.
results
After a number of iterations to develop the method, 
the coregistration and integration of presurgical MRS and 
PET data into the neuronavigation systems was successful.
The spherical targets were readily identifiable on the 
neuronavigational system in the operating theater envi-
ronment, which enabled confident targeting of biopsy and 
tumor sampling. This method was developed after initial 
trials of using cross-type targets to represent integrated 
imaging data failed to suitably present the tumor-sampling 
targets in the operating theater. In that case, the neuro-
surgeons found it difficult to identify the targets (which 
were 5–10 mm across but effectively only 1 mm thick) 
and plan the biopsy approach, because the targets readily 
disappeared out of the visualized imaging plane, particu-
larly when they were viewed at an oblique angle rather 
than on an axial plane. In contrast, the spherical targets 
provided simple visualizations that were identified easily 
at any angle and on any of the image planes. Color cod-
ing these spheres provided a method for indicating to the 
neurosurgeons what each of the spheres described, and the 
hollow part of the sphere represented the epicenter of the 
MRS voxel (10 × 10 × 15 mm).
A screenshot of the 3D neuronavigational ultrasound 
system taken during biopsy performed using these images 
is shown in Fig. 2. In that patient, the red hollow sphere 
indicated areas of high Cho, and the blue hollow sphere 
Fig. 1. Integration of PET and MRS into a surgical plan. MRS data are analyzed, and the voxel to be sampled is selected (red). A 
hollow sphere is then placed around this voxel (yellow) to indicate the target area within the center of the sphere to biopsy. PET 
data are analyzed also, and the area to be sampled is indicated using a hollow sphere (red), which is also added to the surgery-
planning image (upper right). By use of this system, MRS and PET data can also be combined to show the spatial correlation 
between the 2 modalities. Images are from a 34-year-old male patient with a histological diagnosis of WHO Grade IV glioblastoma. 
Figure is available in color online only.
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indicated areas of low Cho. Planning images are shown 
together with the preoperative images (T2 weighted in the 
case of the patient shown in the screenshot).
In one case, a region of high Cho metabolism within a 
nonenhancing lesion corresponded to a region of early fo-
cal malignant transformation on a background of a WHO 
Grade II astrocytoma within low Cho components. The 
sample in this area showed mitotic activity indicative of a 
transforming tumor (WHO Grade II–III).
Discussion
Gliomas are frequently spatially heterogeneous, and 
the ability to identify and accurately sample the most ag-
gressive tumor components is essential for correct tissue 
classification and postsurgical treatment stratification, 
which are particularly important when the tumor location 
permits only limited-sampling partial resection or stereo-
tactic biopsy and with nonenhancing, atypical, and multi-
centric lesions. There is a significant body of evidence to 
indicate that physiological MRI methods and molecular 
imaging with PET enable the detection of tumor pheno-
type and heterogeneity, which are not apparent with rou-
tine structural MRI.14
Previously Used techniques
The use of “advanced” imaging to guide biopsy, how-
ever, is less well established. In particular, previous studies 
were not effective in prospectively correlating histopathol-
ogy and MRS accurately. A number of different approach-
es have been described in published reports.
Some studies recorded the biopsy site on T1- or T2-
weighted images during surgery and retrospectively corre-
lated them with MRS data.3,4 This technique is not usable 
in a prospective cohort in which the aim is to take samples 
from specific areas identified with advanced imaging.
Other reports described hard-copy MR images present-
ed to the surgeon in the operating theater who then used 
the hard copy to identify the MRS voxel location.9 This 
method is prone to increased errors in target sampling, 
and satisfactory postsurgical verification of the biopsy lo-
cation is also not possible. As part of developing the tech-
nique presented here, we experimented with this method, 
which proved cumbersome in practice and prolonged the 
surgical procedure unacceptably. Identifying targets was 
particularly difficult when the optimum plane of imaging 
for the surgical approach differed from the axial plane on 
which spectroscopy was acquired. The required sampling 
locations in these cases could not be represented on the 
correct plane on the hard-copy images.
Intraoperative MRI has been used to target tissue based 
on single-voxel MRS data acquired with structural MRI.13 
This method has the potential advantage of enabling cor-
rection for brain shift by updating the metabolically de-
fined target during surgery. However, intraoperative MRI 
is costly and available in very few centers, often requires 
the presence of a radiologist to analyze the images, and 
is recognized to lengthen the duration of surgical proce-
dures. Intraoperative MRS is also technically challenging 
and prone to artifacts from tissue-air interfaces around the 
exposed tumor1 that can markedly degrade the metabolic 
data acquired. 
A fourth method that has been described involves ac-
quiring a separate 5-slice T1-weighted image for the lo-
cation of MRS and copying the MRS results onto this 
5-slice T1-weighted image before loading the MRS data 
into a color map of the Cho/N-acetylaspartate ratio onto 
the neuronavigational system.17,20 This method is less 
Fig. 2. System in use in the operating theater. A screenshot from the SonoWand system shows the presurgery MR images (left), 
the surgery plan (center), and the ultrasound overlaid image (right) at 2 different oblique angles (upper and lower). The ultra-
sound images provide near real-time surgery guidance. The 3D color-coded hollow spheres enable easy identification of targets 
at any angle. The green markers indicate from where the sample was taken during surgery. Images are from a 34-year-old male 
patient with a histological diagnosis of WHO Grade II astrocytoma. Figure is available in color online only.
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accurate than using the spatial localization informa-
tion available within the MRS data set, and it increases 
the complexity of the surgery by introducing an image-
analysis step at the point of performing the biopsy. It also 
requires pre-analysis of the MRS data to ensure that the 
quality of the data within the various voxels from which 
the color maps are derived are sufficient for meaningful 
interpretation.
In some regards, representing PET on neuronaviga-
tional systems is more straightforward than representing 
MRS, because it generates a series of images rather than 
spectra. That said, the appropriate selection of intensity 
level and width “windows” is necessary to enable visu-
alization of different regions of abnormal tracer uptake. 
Even when the intensity level and width window had been 
optimized on a PET workstation, however, we found that 
regions of elevated uptake were not always conspicuous 
when PET images were fused directly onto the neuronavi-
gational system. The close inspection and interpretation 
of the images that were required prolonged the surgical 
procedure. Pre-selection and representation of targets us-
ing the hollow-sphere method circumvented this problem.
the Developed tool
We developed and implemented a usable method for 
MRS- and PET-guided biopsy that involves the following 
3 steps.
Offline Processing, Analysis, and Interpretation of Data
Multivoxel MRS (Fig. 4) enables metabolite profiles to 
be mapped over a sizeable and defined volume of tissue. 
Cho/Cr and Cho/N-acetylaspartate ratios are known to be 
different among low- and high-grade tumors,19 and high-
Cho regions provide potential indicators of aggressive tu-
mor components in diffuse gliomas. The spectra require 
offline processing and analysis and an understanding of 
technical factors and artifacts that are critical for reliable 
interpretation. Therefore, processing and analysis were 
performed by a neuroradiologist and imaging scientist ex-
perienced with in vivo MRS, using proprietary and open-
source software for processing, analysis, and manual voxel 
target selection.
High- and low-uptake targets also were selected manu-
ally from appropriately windowed static FMC PET im-
ages derived from dynamic acquisition.
Reliable Coregistration of Physiological/Molecular Images With 
High-Resolution Structural Data Sets
Spectroscopy generates biochemical maps that lack 
structural features, which precludes the use of rigid-body 
registration methods that are typically used to fuse func-
tional and structural images. We therefore developed soft-
ware to extract coordinates from the spectroscopy-acqui-
sition parameters, which could be coregistered with the 
volumetric MRI data sets.
Fig. 3. System in use in the operating theater. A screenshot from the StealthStation system shows the surgery plan on the presur-
gery MR images. In this case, grayscale images were required. The crosshairs mark the area from which the biopsy was taken. 
Images are from a 23-year-old female patient with a histological diagnosis of WHO Grade II oligodendroglioma.
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Coregistration of PET and structural high-resolution 
MRI data is a more straightforward process, and it was 
carried out using well-established rigid-body algorithms 
available in Vinci.
Generation of Targets That Can Be Integrated and Used in 
Neuronavigation Systems in the Operating Theater
Our approach was to synthesize hollow virtual-target 
spheres centered on the feature of interest in MRS or PET 
images. Color coding enabled tissue samples to be labeled 
simply and subsequently correlated with imaging features.
One of our priorities was to develop a methodology that 
optimizes tissue sampling with minimal negative impact 
on the complexity and length of surgical procedures. Such 
a guidance tool can be used mainly in the following 2 ways.
The first use is multimodal imaging to guide biopsy and 
tumor sampling to optimize glioma tissue characterization 
for clinical stratification. Although this was not a prima-
ry aim of our study, in one patient, high-Cho regions re-
vealed histological evidence of malignant transformation 
in a WHO Grade II lesion that altered subsequent clinical 
management. This approach can also be used to optimize 
the resection of aggressive tumor components and evalu-
ate its effects on survival.
The second use is for validating current and emerging 
imaging biomarkers against tissue biomarkers in defined 
regions of tissue. This validation was the primary aim of 
the research study to which patients were recruited and for 
which this tool was initially developed.
limitations
Considerable processing and analyses are required for 
presurgical planning, which is labor intensive and requires 
both specialist neuroradiology and imaging clinical scien-
tist expertise. This requirement is particularly critical for 
patients with a short lead time in between imaging and sur-
gery. Furthermore, the formats of imaging data produced 
by different MRI platforms and required by commercial 
neuronavigational systems might be vendor specific, and 
processes might need modification for individual combi-
nations of equipment. For example, our StealthStation and 
an older SonoWand system would not allow the display of 
color-coded images. Moreover, we developed the tool for 
use on Siemens MRI data sets, and it is likely that modifi-
cations to the MATLAB code would be required for data 
sets from other vendors. The code we developed to extract 
the MRS spatial locations can be provided on request for 
other researchers to test.
The exact accuracy and precision with which regions 
of interest, chosen as targets, are represented in the neuro-
navigation system are difficult to determine reliably. Our 
targets are coregistered on presurgical images and do not 
take into account ≥ 1-cm brain shifts that can occur dur-
ing an operation.2,16 Because the stereotactic biopsies were 
performed before tumor resection, the degree of target 
misalignment is likely to have been small, although a mi-
nor shift might have occurred as a result of the craniotomy 
alone. Furthermore, the exact location at which the biopsy 
was performed cannot be verified after the tumor is re-
sected because it cannot be imaged after resection. Thus, 
the accuracy of the tool depends on that of the neuronavi-
gational system with which it is used, and factors that limit 
accuracy of the system need to be considered.12
Conclusions
We have developed a targeted PET- and MRS-guided 
stereotactic biopsy tool that uses intraoperative neuro-
navigation that involves a combination of proprietary and 
bespoke software to analyze and integrate physiological 
imaging data and novel presentation of biopsy targets as 
hollow spheres that can readily be identified in the oper-
ating environment. Our preliminary experiences indicate 
that this method can be used to improve the diagnostic ac-
curacy of stereotactic biopsy, provided that the advanced 
Fig. 4. MRS data. Multivoxel MRS data are acquired over large areas of tumor, and a spectrum showing the different metabolites 
can be seen in each voxel area. In this case, areas of moderate Cho were observed in the tumor. Figure is available in color online 
only.
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imaging techniques (in this case, PET and MRS) included 
in the planning system can indicate more aggressive areas 
of an otherwise heterogeneous tumor. Our results also pro-
vide proof of principle for spatially correlated validation 
of a variety of imaging biomarkers against tissue features.
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